Predicting Lipid-Lowering Medication Persistence after the First Cardiovascular Disease Hospitalization

被引:1
|
作者
Hu, Feiyu [1 ]
Warren, Jim [1 ]
Exeter, Daniel J. [2 ]
机构
[1] Univ Auckland, Sch Comp Sci, Private Bag 92019, Auckland, New Zealand
[2] Univ Auckland, Sch Populat Hlth, Auckland, New Zealand
关键词
medication persistence; cardiovascular diseases; machine learning; prediction models; ARTIFICIAL NEURAL-NETWORK; CORONARY-HEART-DISEASE; SECONDARY PREVENTION MEDICATIONS; DECISION-SUPPORT-SYSTEM; MYOCARDIAL-INFARCTION; NEW-ZEALAND; LOGISTIC-REGRESSION; STATIN THERAPY; RISK-FACTOR; ADHERENCE;
D O I
10.1055/s-0040-1713905
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Objectives This study analyzed patient factors in medication persistence after discharge from the first hospitalization for cardiovascular disease (CVD) with the aim of predicting persistence to lipid-lowering therapy for 1 to 2 years Methods A subcohort having a first CVD hospitalization was selected from 313,207 patients for proportional hazard model analysis. Logistic regression, support vector machine, artificial neural networks, and boosted regression tree (BRT) models were used to predict 1- and 2-year medication persistence Results Proportional hazard modeling found significant association of persistence with age, diabetes history, complication and comorbidity level, days stayed in hospital, CVD diagnosis type, in-patient procedures, and being new to therapy. BRT had the best predictive performance with c-statistic of 0.811 (0.799-0.824) for 1-year and 0.793 (0.772-0.814) for 2-year prediction using variables potentially available shortly after discharge. Conclusion The results suggest that development of a machine learning-based clinical decision support tool to focus improvements in secondary prevention of CVD is feasible.
引用
收藏
页码:61 / 74
页数:14
相关论文
共 50 条
  • [1] Interrupted time series analysis on first cardiovascular disease hospitalization for adherence to lipid-lowering therapy
    Hu, Feiyu
    Warren, Jim
    Exeter, Daniel J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 (02) : 150 - 160
  • [2] Landmark Lipid-Lowering Trials in the Primary Prevention of Cardiovascular Disease
    Chrispin, Jonathan
    Martin, Seth S.
    Hasan, Rani K.
    Joshi, Parag H.
    Minder, C. Michael
    McEvoy, John W.
    Kohli, Payal
    Johnson, Amber E.
    Wang, Libin
    Blaha, Michael J.
    Blumenthal, Roger S.
    CLINICAL CARDIOLOGY, 2013, 36 (09) : 516 - 523
  • [3] Interventions to improve adherence to lipid-lowering medication
    van Driel, Mieke L.
    Morledge, Michael D.
    Ulep, Robin
    Shaffer, Johnathon P.
    Davies, Philippa
    Deichmann, Richard
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (12):
  • [4] Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease
    Suh, Dong-Churl
    Griggs, Scott K.
    Henderson, Emmett R.
    Lee, Seung-Mi
    Park, Taehwan
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (01) : 51 - 69
  • [5] Lipid-Lowering Medication and Outcomes After Anatomical and Functional Imaging in Suspected Coronary Artery Disease
    Maaniitty, Teemu
    Maenpaa, Matias
    Harjulahti, Esa
    Kujala, Iida
    Stenstrom, Iida
    Nammas, Wail
    Knuuti, Juhani
    Saraste, Antti
    JACC-CARDIOVASCULAR IMAGING, 2025, 18 (01) : 62 - 73
  • [6] Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes
    Cavallari, Ilaria
    Delli Veneri, Alessia
    Maddaloni, Ernesto
    Melfi, Rosetta
    Patti, Giuseppe
    Napoli, Nicola
    Pozzilli, Paolo
    Di Sciascio, Germano
    CURRENT DIABETES REPORTS, 2018, 18 (12)
  • [7] Proactive Pharmaceutical Care Interventions Improve Patients' Adherence to Lipid-Lowering Medication
    Stuurman-Bieze, Ada G. G.
    Hiddink, Eric G.
    van Boven, Job F. M.
    Vegter, Stefan
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (11) : 1448 - 1456
  • [8] Lipid-Lowering Therapy with Statins for the Primary and Secondary Prevention of Cardiovascular Disease
    Lardizabal, Joel A.
    Deedwania, Prakash
    CARDIOLOGY CLINICS, 2011, 29 (01) : 87 - +
  • [9] Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention
    Smith, Bryan A.
    Wright, Charmaine
    Davidson, Michael
    CURRENT ATHEROSCLEROSIS REPORTS, 2015, 17 (12)
  • [10] Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis
    Kam, Ning
    Perera, Kanila
    Zomer, Ella
    Liew, Danny
    Ademi, Zanfina
    PHARMACOECONOMICS, 2020, 38 (09) : 1007 - 1020